Preview

Obstetrics, Gynecology and Reproduction

Advanced search

MORTALITY OF PREMATURELY BORN NEWBORNS WITH RESPIRATORY DISTRESS SYNDROME RECEIVED PORACTANT ALPHA

https://doi.org/10.17749/2313-7347.2016.10.4.049-053

Full Text:

Abstract

Objective: to estimate efficiency of treatment with poractant alpha of premature newborns with respiratory distress syndrome and to define possibilities of its increase on the example of obstetrical medical centers in Azerbaijan.

Materials and methods. we examined routine practice of poraktant alfa usage in premature newborns with respiratory distress syndrome during 2014-2015.

Results. The general level of lethality among newborns with respiratory distress syndrome with poractant alfa herapy was 25.3%.

Conclusions. The use of poractant alpha for treatment of prematurely newborns with respiratory distress syndrome allows to keep life till 74.7% of patients. There is correlation between efficiency of treatment with poraktant alfa and weight of newborn.

About the Author

S. N. Mamedova
Republican Perinatal Center
Azerbaijan

PhD, doctoral student Department of Obstetrics and Gynecology, the Azerbaijan Medical University; Director of the Republican Perinatal Center,

ul. Yusif Safarov, 22, Baku, Khatai, AZ1025



References

1. Keeping infants with respiratory distress syndrome. Clinical guidelines. Ed. Acad. RAS NN Volodin. Approved by the President of the Russian Association of perinatal medicine specialists [Vedenie novorozhdennykh s respiratornym distresssindromom. Klinicheskie rekomendatsii. Pod red. akad. RAN N.N. Volodina. Utverzhdeny Prezidentom Rossiiskoi Assotsiatsii spetsialistov perinatal'noi meditsiny (in Russian)]. 2015; 63 s.

2. Perepelitsa S.A., Golubev A.M., Moroz V.V. Obshchaya reanimatologiya. 2012; VIII (4): 95-101.

3. Basis of newborns with respiratory distress syndrome. Guidelines [Printsipy vedeniya novorozhdennykh s respiratornym distresssindromom. Metodicheskie rekomendatsii (in Russian)]. www.RASM.net. Accessed: 20.09.16.

4. Stenton G. Mediko-biologicheskaya statistika. M. 1999; 459 s.

5. Andrea T., Christoph P.H., Reese C. et al. Comparative effectiveness of three surfactant preparations in premature infants. J Pediatr. 2013 October; 163 (4): 955-960.

6. Dani C., Ravasio R., Fioravanti L. Circelli M. Analyisis of the cost-effectiveness of surfactant treatment (Curosurf) in respiratory distress syndrome therapy in preterm infants; early treatment compared yo late treatment. Italian journal of pediatrics. 2014; 40 (40).

7. Dargaville P.A., Kamlin C.O., Paoli A.G. et al. The optimist-a trial: evaluation of minimally-invasive surfactant therapy in preterm infants 25-28 weeks gestation. BMC Pedriatrics. 2014; 14: 213.

8. Jeon G.W., Sin J.B. Efficacy of Surfactant – TA, Surfactant and Poractant alfa for preterm infants with respiratory distress syndrome; a retrospective Study. Yonsei Med S. 2015; 56 (2): 433-439.

9. Ramanathan R., Sekar K., Ernst F.R. Mortality in preterm infants with respiratory distress syndrome treated with poractant alfa, Calfaktant or beractant: a retrospective study. Journal of Perinatology. 2013; 33: 119-125.


For citation:


Mamedova S.N. MORTALITY OF PREMATURELY BORN NEWBORNS WITH RESPIRATORY DISTRESS SYNDROME RECEIVED PORACTANT ALPHA. Obstetrics, Gynecology and Reproduction. 2016;10(4):49-53. (In Russ.) https://doi.org/10.17749/2313-7347.2016.10.4.049-053

Views: 111


ISSN 2313-7347 (Print)
ISSN 2500-3194 (Online)